Emerging Company Profile
Amphista: broadening the target space of protein degradation
Amphista raised $7.5M to test its targeted protein degradation platform in vivo
Amphista raised $7.5M to test its E3 ligase-independent targeted protein degraders in vivo.
Amphista aims to apply protein degradation to a broader set of targets and indications using an approach